A Phase 1, Open-Label, Dose-Escalation with Expansion Study of SX-682 in Subjects with Myelodysplastic Syndrome Who Had Disease Progression or are Intolerant to Prior Therapy
This study is currently enrolling.
This research study is studying an investigational immunotherapy called SX-682 as a possible treatment for Myelodysplastic Syndrome.